Peter Attia MD177 - The development of cancer immunotherapy and its promise for treating advanced cancers
At a glance
WHAT IT’S REALLY ABOUT
Steve Rosenberg Traces Cancer Immunotherapy From Failures to Personalized T Cell Cures
- Rosenberg describes how a childhood shaped by the Holocaust and two early patients, one with spontaneous cancer regression and one whose tumor vanished after immunosuppression was stopped, pushed him toward immune-based cancer treatment.
- He explains that metastatic solid cancers are essentially incurable with surgery, radiation and chemotherapy, and that immunotherapy appealed because of its exquisite selectivity for tumor versus normal cells.
- The episode traces the arc from LAK cells and the first interleukin-2 response in 1984 (after over 70 patients) to TIL therapy, gene-marking of lymphocytes, and the CAR T cell work that led to Kite Pharma.
- Rosenberg reports that about 80% of patients with common epithelial cancers have T cells recognizing unique, patient-specific mutations, which makes broad application possible but demands individualized treatment.
- The conversation closes on lessons from his career: radical openness in science, staying at the bedside through failures, and the family support that sustained his work.
IDEAS WORTH REMEMBERING
5 ideasImmunotherapy's appeal is its selectivity
Rosenberg says chemo and radiation cannot distinguish cancer from normal cells, while the immune system can recognize even single amino acid changes in a protein.
Persistence through failure preceded the first success
More than 70 patients were treated with interleukin-2 or IL-2-grown cells without a response before a modified high-dose schedule produced a melanoma regression in 1984, and that patient remains disease-free decades later.
Mutations are the key antigens for most cancers
Rosenberg's group found T-cell-recognized mutation antigens in about 80% of 195 patients, with essentially every antigen unique to the individual, and only a small fraction of mutations (1.5-2%) being immunogenic.
Individualization is both a promise and a scaling problem
Because antigens are patient-specific, treatments must be customized, but Rosenberg argues that if a therapy cures people, industry will find ways to deliver it, as happened with CAR T cells.
CAR T cells work for blood cancers but not yet solid tumors
CD19 is present on B cells and the lymphomas arising from them, so losing normal B cells is survivable; for solid cancers no antigen unique to tumor has been found, and targeting normal-cell antigens has killed patients.
WORDS WORTH SAVING
5 quotesI knew from the very beginning that I wasn't just gonna try to practice today's science, practice today's medicine, but rather try to create the medicine of tomorrow
— Steve Rosenberg
if a cancer spreads from its local site and cannot be surgically removed, then the death rate in that patient is a hundred percent.
— Steve Rosenberg
Chance favors the prepared mind only if the mind is at work.
— Steve Rosenberg
Sort of ironic that the Achilles' heel of the cancer is gonna be the very abnormalities that caused it in the first place.
— Steve Rosenberg
It's not like we're trying to, to create a better air conditioner. We're trying to save the life of another, uh, another human being.
— Steve Rosenberg
High quality AI-generated summary created from speaker-labeled transcript.
